“Guided by its commitment to advancing next-generation bio-technologies and improving quality of life, Samsung C&T has continuously invested in innovative companies. The collaboration with GRAIL represents a significant new step—moving beyond investment to a strategic business partnership that provides Samsung with a strong foothold for expanding into the cancer screening field and delivering one of these promising technologies to customers in South Korea and across Asia.” said Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T.

Subject to final execution of definitive agreements, GRAIL and SCT will work as exclusive partners to commercialize the Galleri test in South Korea, with a possible extension into other Asian geographies, including Japan and Singapore. SCT will undertake key activities to drive adoption of Galleri . Initially, tests will be performed in GRAIL’s clinical laboratory in Research Triangle Park, North Carolina.

“We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea,” said Sir Harpal Kumar, President, International Business & Biopharma, at GRAIL. “Samsung’s significant equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets.”

In addition, SEC and GRAIL intend to explore potential strategic and operational collaborations such as supporting longitudinal genomic-lifestyle clinical research, and the integration of SEC’s health data platform with GRAIL’s technologies and data.

“Our investment in and strategic cooperation with GRAIL is part of our vision to improve the health of billions of people. A potential collaboration with GRAIL could allow for the integration of our AI, our digital care platform, and device ecosystem with GRAIL’s clinical genetic data and technology, which could allow us to provide a level of personalization for our users to help them better understand their health,” said Hon Pak, Senior Vice President and Head of Digital Health Team, Mobile eXperience Business, at Samsung Electronics.

The terms of the collaborations are set forth in the term sheets between the parties. Definitive agreements will be negotiated in good faith pursuant to the term sheet and are intended to be entered into in early 2026. Commercial operations will begin soon after execution. Within South Korea, and potentially Japan and Singapore, GRAIL will partner with SCT as its sole distributor, subject to certain requirements, and GRAIL’s Galleri test will be the exclusive MCED test distributed by SCT.

The investment is subject to execution of the definitive collaboration agreements between the parties, as well as customary closing conditions and regulatory approvals. The investment is expected to close in early 2026.

Latham & Watkins served as legal advisor and Morgan Stanley & Co. LLC served as financial advisor to GRAIL. Samsung was advised by Covington & Burling, BKL, and E&Y Han Young (Korea).

¹ Representing a 10% premium to the 15 day VWAP.

About Samsung C&T Corporation

Samsung C&T Corporation, a dynamic player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in the fields of biopharmaceutical and life sciences. Since its investment in Samsung Biologics and Samsung Bioepis, Samsung C&T continues to invest in innovative technologies and businesses within the bio and healthcare sectors, with the goal of contributing to improving the quality of human life.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

About Galleri^®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear — when they can be easier to treat and are potentially curable². Galleri is the only available MCED test with demonstrated performance in patients screened for cancer^2,*. The Galleri test doubles the number of cancers detected when added to standard of care cancer screening, and has the lowest false positive rate of any MCED test^1,2,3,4,**. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up^4,5,6. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

For more information, visit galleri.com.

* The Galleri test performance metrics were derived from the outcomes of an interventional clinical study of patients presenting for screening without clinical suspicion of cancer, a study population that reflects the intended use population.

** Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.

Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988.

(CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations and projections of our ability to negotiate definitive agreements, the closing of the investment, the terms under which we will conduct our collaborations, future potential additional collaborations, our ability to commercialize Galleri in other geographies, success of our collaboration with counterparties, sufficiency of cash on hand to finance our business and anticipated trends in our business.

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2024 and in our Quarterly Report on [Form 10-Q for the period ended June 30, 2025] (the “Form 10-Q”). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

References:

1. Nabavizadeh N, et al. Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study. Proffered Presentation Presented at: European Society for Medical Oncology (ESMO) Annual Meeting; October 17-21, 2025; Berlin, Germany.
2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
3. GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]
4. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2
5. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
6. Hackshaw A, et al. Cancer Cell. 2022;40(2):109-13.

To explore these themes further, Samsung hosted two panels at the Galaxy Tech Forum on July 10 in Brooklyn. Samsung Newsroom joined industry leaders and executives to examine how ambient intelligence and advanced health technologies are shaping the future of mobile innovation.

(Panel One) The Next Vision of AI: Ambient Intelligence

▲ (From left) Moderator Sabrina Ortiz, Jisun Park, Mindy Brooks and Dr. Vinesh Sukumar

The first panel, “The Next Vision of AI: Ambient Intelligence,” explored how multimodal capabilities are enabling the continued evolution of AI in everyday life — blending into user interactions in ways that feel intuitive, proactive and nearly invisible. Panelists discussed the smartphone’s evolving role, the importance of platform integration and the power of cross-industry collaboration to deliver secure, personalized intelligence at scale.

Jisun Park, Corporate Executive Vice President and Head of Language AI Team, Mobile eXperience (MX) Business at Samsung Electronics, opened the conversation by reflecting on Galaxy AI’s rapid adoption. Since the launch of the Galaxy S25 series in January, more than 70% of users have engaged with Galaxy AI features. He then turned the discussion to the next frontier, ambient intelligence — AI that is deeply personal, predictive and ever-present.

▲ Jisun Park from Samsung Electronics

Samsung sees ambient intelligence as AI that is so seamlessly integrated into daily life it becomes second nature. The company is committed to democratizing Galaxy AI to 400 million devices by the end of 2025.

This vision builds on insights from a yearlong collaboration with London-based research firm Symmetry, which revealed that 60% of users want their phones to anticipate needs without prompts — based on daily habits.

“Some see AI as the start of a ‘post-smartphone’ era, but we see it differently,” said Park. “We’re building a future where your devices don’t just respond — they become smarter to anticipate, see and work quietly in the background to make life feel a little more effortless.”

Mindy Brooks, Vice President of Android Consumer Product and Experience at Google, discussed how multimodal AI is moving beyond reactive response to deeper understanding of user intent across inputs like text, vision and voice. Google’s Gemini is designed to be intelligently aware and anticipatory — tuned to individual preferences and routines for assistance that feels natural.

▲ Mindy Brooks from Google

“Through close collaboration with Samsung, Gemini works seamlessly across its devices and connects with first-party apps to provide helpful and personalized responses,” she said.

Dr. Vinesh Sukumar, Vice President of Product Management at Qualcomm Technologies emphasized that as AI becomes more personalized, there is more information than ever that needs to be protected.

“For us, privacy, performance and personalization go hand in hand — they’re not competing priorities but co-equal standards,” he said.

▲ Dr. Vinesh Sukumar from Qualcomm Technologies

Both Brooks and Dr. Sukumar reinforced the importance of tight integration across platforms and hardware.

“Our work with Samsung prioritizes secure, on-device intelligence so that users know where their data is and who controls it,” said Dr. Sukumar.

▲ The AI panel at Galaxy Tech Forum

Moderator Sabrina Ortiz, senior editor at ZDNET, closed the session with a discussion on AI privacy. Panelists agreed that trust, transparency and user control must underpin the entire AI experience.

“When it comes to building more agentic AI, our priority is to ensure we’re fostering smarter, more personalized and more meaningful assistance across our device ecosystem,” said Brooks.

(Panel Two) The Next Chapter of Health: Scaling Prevention and Connected Care

The second panel, “The Next Chapter of Health: Scaling Prevention and Connected Care,” focused on how technology can bridge the gap between wellness and clinical care — making health insights more connected, proactive and usable for individuals, healthcare providers and digital health solution partners. Panelists explored how the convergence of clinical data, at-home monitoring and AI is reshaping the modern healthcare experience.

▲ (From left) Moderator Dr. Hon Pak, Mike McSherry, Dr. Rasu Shrestha and Jim Pursley

Health data is often siloed across systems, resulting in inefficiencies and gaps in care. Combined with rising rates of chronic illness, an aging population and ongoing clinician shortages, the result is a system under pressure to deliver timely, effective care.

▲ Dr. Hon Pak from Samsung Electronics

“Patients and consumers around the world are asking us to hear them, to know them, to truly understand them,” said moderator Dr. Hon Pak, Senior Vice President and Head of Digital Health Team at Samsung Electronics. “And I believe this is the opportunity we have with Samsung, Xealth and partners like Hinge and Advocate. Together, we are creating a connected ecosystem where healthcare can truly make a difference — not just in the life of a patient, but in the life of a person.”

Samsung is addressing this challenge through technological innovation and its recent acquisition of Xealth, a leading digital health platform with a network of more than 500 hospitals and 70 digital health solution providers. Through Xealth, Samsung plans to connect wearable data and insights from Samsung Health into clinical workflows — delivering a more unified and seamless healthcare experience.

▲ Mike McSherry from Xealth

“This [phone], plus your devices — the watch, the ring — are going to replace the standalone blood pressure monitor, the pulse oximeter, a variety of different devices,” said Mike McSherry, founder and CEO of Xealth. “It’s going to be one packaged solution, and that’s going to simplify care.”

This collaboration is designed to empower hospitals with real-time insights and help prevent chronic conditions through early detection and continuous monitoring with wearable devices.

▲ Dr. Rasu Shrestha from Advocate Health

“The reality is that with all of the challenges that exist in healthcare, it is not any one entity that can heroically go in and save healthcare. It really takes an ecosystem,” said Dr. Rasu Shrestha, Executive Vice President and Chief Innovation & Commercialization Officer at Advocate Health. “That’s part of the reason why I’m so excited about Xealth and Samsung — and partners like us — really coming together to solve for this challenge. Because it is about Samsung enabling it. It’s more of an open ecosystem, a curated ecosystem.”

The panel spotlighted the growing shift from hospital-based care to care at home — and the opportunities enabled by Samsung’s expanding ecosystem of connected devices. Data from wearables, including those equipped with Samsung’s BioActive Sensor technology, can provide high-quality input for AI-driven insights.

Paired with Samsung’s SmartThings connectivity and wide portfolio of smart home devices, the company is uniquely positioned to support remote health monitoring and treatment from home.

AI is expected to play a role in reducing clinician workload by streamlining administrative tasks and surfacing the most relevant insights at the right time. Platforms like Xealth offer users a personalized, friendly interface to access necessary information from one place for a more connected healthcare experience.

▲ The health panel at Galaxy Tech Forum

Across both sessions, one theme was clear — realizing the potential of ambient intelligence and scaling prevention and connected care requires deep, cross-industry collaboration.

From on-device privacy solutions like Knox Matrix to expanded integration across Galaxy devices, Samsung and its partners are building an ecosystem that’s not only intelligent but simple, secure and future-ready.

With over 25 years of experience in the medical field and now as Head of Digital Health team at Samsung Electronics, I spend a lot of time contemplating how technology can truly drive progress in healthcare, rather than being just another innovation for innovation’s sake. That’s why I’m very excited about AI as it offers new ways to address many of society’s health problems by simplifying complexity and at scale.

In our ongoing work to reimagine healthcare, Samsung is leveraging advanced AI algorithms and extensive technical expertise to develop solutions like Energy Score. This feature quantifies physical and mental energy levels through multiple health indicators including sleep, heart health and physical activity. Our vision is to include more comprehensive metrics like nutrition, mental health and additional mobile usage patterns to provide a holistic view of users’ health status, powered by AI.

AI holds great promise for early disease prevention through analyzing patterns and behaviors, detecting abnormalities, and even predicting potential health issues. By combining our long-standing sensor innovations with AI leadership, we aim to elevate our capabilities in preventing diseases, beyond sleep apnea and expanding to cardio-metabolic conditions. In particular, blood glucose is a big area of focus for us, and Samsung has been working to develop a sensor algorithm that predicts early signs of diabetes — along with non-invasive blood glucose monitoring technology and continuous glucose monitoring-integrated nutrition coaching.

Our goal is to support proactive health management, lowering healthcare burdens on individuals, families and communities at large. I strongly believe that AI will revolutionize the digital health industry and simplify the wellness journey for everyone. As a global tech leader, Samsung is uniquely equipped to make this a reality with our mix of technology innovations and a growing ecosystem of partners.

The release of OmniTom^® is the latest demonstration of Samsung’s leadership in CT imaging. OmniTom^® features an array of improvements from Samsung’s award-winning CereTom CT scanner, including:

• Improved workflow: OmniTom^® is the world’s first mobile imaging device with omni-directional wheels, maximizing mobility and allowing easier and quieter movement in small spaces.
• Superior image quality: 16-slice (0.625 mm per slice) advanced data acquisition system with a 50 percent increase in CNR versus other portable CT technologies.
• Expanded use: Maintains a small footprint ideal for mobile use while increasing the gantry opening to 40 cm for improved coverage of adult head and neck, and full body pediatric scanning.
• Enhanced safety system: OmniTom^® features an internal drive system, making portability less strenuous, while also offering smart-sensing collision avoidance software to maximize control and patient safety.

OmniTom^® is ideal for cranial procedures and is designed to deliver the highest quality non-contrast CT, CT angiography and CT perfusion scans. The combination of its rapid scan time, ultra-small footprint and immediate image viewing makes OmniTom^® an indispensable tool for collecting real-time data on critically ill patients.

The latest product also demonstrates Samsung’s “AccE” (Access, Accuracy and Efficiency) strategy that aims to change the industry by incorporating innovations in physical access to provide care wherever it is needed. It also aims to improve accuracy in diagnosis with advanced algorithms and efficiency with advanced display, UX and information management technology developed by Samsung Electronics.

“OmniTom^® embodies Samsung’s commitment to providing leading technologies to healthcare providers by combining our key values of Access, Accuracy and Efficiency,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “We’ve made a CT product that’s lighter, more mobile, more accurate and faster, and we hope the many doctors and technicians here at RSNA will be able to use it to benefit their patients.”

“At Samsung, we work tirelessly to make sure that our full range of products provide patients and physicians with the best possible options for care” added Philip Sullivan, President and CEO Samsung NeuroLogica. “We do this through designing products that deliver broad access, superior accuracy and quality, and make care teams more efficient by maximizing throughput and minimizing waste.”

In addition to OmniTom^®, Samsung will be showcasing its spectral CT with Photon Counting Detector (PCD), the next generation of CT technology. Samsung’s team will also be demonstrating a range of healthcare solutions in mobile CT, Digital Radiography and Ultrasound that are all designed to bridge the care-delivery gap and maximize efficiency to enhance the patient experience. Such solutions include:

• Ultrasound Segment: Samsung will feature their comprehensive general imaging ultrasound portfolio, including the new HS60 and HS40 ultrasound systems which were introduced earlier this year. The RS80A with Prestige, Samsung’s premium general imaging ultrasound system, will be displayed in three daily educational demonstrations featuring live scanning. The RS80A includes innovative technologies for the busy radiology department that help boost clinical confidence. Based on its achievements in ultrasonic diagnosis devices for obstetrics and gynecology, the company is strengthening its premium ultrasonic diagnosis device business for radiology, which has the biggest market potential.

• Digital Radiography Segment: Samsung will display a wide range of its portfolio including two ceiling-mounted systems, GC85 and GC70, as well as highlight its premium portable GM85 X-ray. The GM85’s enhanced mobility and streamlined workflow will enable users to experience a new level of efficiency along with exceptional image quality. Samsung has also differentiated itself from its competitors by adopting low dose technology for enhanced patient safety.

• Magnetic Resonance Imaging Segment: Samsung will be showcasing a prototype of Specialty MRI, an MRI imaging device for arms and/or legs. The prototype is expected to be a game changer in the industry: It is designed to maximize not only cost and space but also patient convenience, as it eliminates the need for the whole body to be in the MRI device.

Learn more by visiting Samsung at booth #2543 (South Building, Hall A) at the RSNA 2017 Annual Meeting, as well as following Samsung NeuroLogica on Facebook, Twitter and LinkedIn.

About Samsung NeuroLogica

Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies, and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. Samsung NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit www.SamsungNeuroLogica.com.

UOG is the official journal published by the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). The image that the publication selected represents a breakthrough for Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics. Its fetal echocardiography technology called 5D Heart Color allows a precise diagnosis of congenital heart disease.

The clinical image was obtained from a 26-week fetus with hypoplastic left heart and coarctation of the aorta, in which nine standard fetal echocardiography views with automatic labeling were displayed on a single screen.

The story behind the image can be found in a research paper led by Prof. Roberto Romero, Chief of the Perinatology Research Branch of the National Institute of Child Health and Human Development (NICHD)/National Institutes of Health in the U.S., and Prof. Lami Yeo, M.D., from the Department of Obstetrics and Gynecology at the Wayne State University School of Medicine in Detroit, U.S.

According to the research, the Picture of the Month illustrates how the cardiac diagnostic planes shown by 5D Heart Color (i.e. color Doppler FINE – Fetal Intelligent Navigation Echocardiography) allowed a precise diagnosis of hypoplastic left heart with coarctation of the aorta, and that such planes demonstrated evidence of abnormal fetal cardiac anatomy and hemodynamic flow.

The publication stated, “The characteristic features of this congenital heart defect were visualized in the seven echocardiography views. In the four-chamber view, the left side of the heart was severely hypoplastic with absent flow through the atretic mitral valve, and the aortic arch view showed a very narrow transverse aortic arch (coarctation) with reversed color Doppler flow in this area and the isthmus.”

Samsung’s 5D Heart Color provides nine different fetal echocardiography views containing clinically useful information about cardiac structure and function, including the three vessels and trachea view, four-chamber view, left and right ventricular outflow tract views, aortic arch view, and four others. In cases of congenital heart disease, since abnormal fetal cardiac anatomy and hemodynamic flow characteristics are depicted, this enhances the diagnostic potential of the technology. In addition, there is reduced operator dependency, and examination of the fetal heart is standardized and simplified.

As 5D Heart Color marks the second time Samsung Medison’s technology has been selected as Picture of the Month, (The company’s Crystal Vue also gained the honor in 2016) it’s an illustration of how Samsung Medison is continuing to establish its brand power in the global women’s health industry by providing technology with clinical value to medical professionals.

“It is exciting to see 5D Heart Color is being featured on the front cover of UOG, especially since the diagnostic accuracy of 5D Heart was presented at last month’s World Congress on Ultrasound in Obstetrics and Gynecology,” said Insuk Song, Vice President of the Health & Medical Equipment of Samsung Electronics. “Samsung will continue to focus on developing medical technology that can improve the detection of fetal congenital heart disease and contribute to saving more lives.”

With the powerful combination of SAMSUNG ARTIK Cloud and T-Mobile, companies like Breezie don’t have to sacrifice interoperability with other connected devices and services. The easy onboarding and interoperability of SAMSUNG ARTIK Cloud allows connected devices – such as Amazon Alexa, Samsung SmartThings, iHealth Feel Wireless Blood Pressure Monitor and the Pulse Oximeter – to intelligently communicate with each other. SAMSUNG ARTIK Cloud also offers a simplified development process that shortens time to market and enables healthcare solution platforms to focus on differentiation and innovation.

“We are proud that Breezie selected SAMSUNG ARTIK Cloud and T-Mobile as their IoT solution partners,” said James Stansberry, senior vice president and U.S. head of SAMSUNG ARTIK Smart IoT platform. “Through the SAMSUNG ARTIK Cloud and T-Mobile platform, Breezie and other leading healthcare companies can utilize the power of the IoT to provide better healthcare services, improve the lives of patients and reduce costs.”

“Together, T-Mobile and SAMSUNG ARTIK Cloud are removing the pain points in healthcare and IoT to deliver a market leading platform to customers,” said Doug Chartier, senior vice president of MVNO, IoT and national retail at T-Mobile. “By joining forces with SAMSUNG ARTIK Cloud, we’ve streamlined the process for companies to bring their connected IoT solutions to market.”

The Samsung ARTIK Cloud is part of the SAMSUNG ARTIK Smart IoT platform that unifies hardware, software, cloud, security and partner ecosystems in a single offering so that enterprises and healthcare companies can reduce the time, cost and risk typically associated with the delivery of complex IoT solutions. SAMSUNG ARTIK Cloud complies with HIPAA requirements.

“After assessing available options, the combination of T-Mobile and SAMSUNG ARTIK Cloud was the best IoT development solution to enable us to deliver a highly personalized IoT experience at scale,” said Jeh Kazimi, founder and CEO of Breezie. “The IoT offering allows Breezie to extend interface capabilities to a wide range of IoT devices, smart sensors and Bluetooth remote monitoring devices.”

Breezie’s Samsung tablet-based platform radically simplifies the complexities of connected devices to improve care and services for elderly individuals, as well as support day-to-day lives and post-surgical recovery. Each Breezie interface has more than 40 preconfigured accessibility settings and sensor driven analytics to adjust for different levels of digital literacy, as well as physical and cognitive ability.

To learn more about Breezie and Samsung, stop by booth 3673, and meeting rooms MP75 and MP76 at HIMSS17.

About SAMSUNG ARTIK Cloud

SAMSUNG ARTIK Cloud is an open data exchange platform for the Interoperability of Things (IoT). ARTIK Cloud provides easy-to-use, open APIs and tools to securely collect, store, and act on any data from any connected device or cloud service. ARTIK Cloud is designed to accelerate time to market and revenue of a new generation of IoT solutions and services. More information about Samsung ARTIK Cloud can be found at http://artik.cloud

About T-Mobile

As America’s Un-carrier, T-Mobile US, Inc. (NASDAQ: TMUS) is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company’s advanced nationwide 4G LTE network delivers outstanding wireless experiences to 71.5 million customers who are unwilling to compromise on quality and value. Based in Bellevue, Washington, T-Mobile US provides services through its subsidiaries and operates its flagship brands, T-Mobile and MetroPCS. For more information, please visit http://www.t-mobile.com.

About Breezie Inc.

Breezie Inc. is headquartered in Pittsburgh, PA with offices in London, United Kingdom. It offers a personalized, flexible and secure tablet platform that is proven to engage users irrespective of their technical capabilities. Its unique open platform enables healthcare companies to integrate their own proprietary content and third party services with ease.  The Caregiver’s Hub is a powerful engagement tool that allows a family member or caregiver to remotely select and personalize the services most relevant to the user. CDW and Samsung are partnering with Breezie to sell an integrated solution to that takes care of everything from hardware, set-up and configuration to ongoing support and warranty. To discover more, please visit www.breezie.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the ability of the collaboration to enhance marketing of health care solutions, improve the lives of patients, and reduce costs, T-Mobile’s and Breezie’s future plans, the potential to produce new apps and services and the platform’s ability to connect with other Internet of Things (IoT) devices.  These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, changes in the healthcare and cloud computing markets and the regulatory environment, difficulties in integrating technologies of the companies in the collaboration, the inability of the new IoT solution to achieve wide market acceptance , and the ability to compete with other products in the market. The companies are providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Visitors to Samsung Electronics’ booth at the Radiological Society of North America’s (RSNA) 2016 annual meeting in Chicago examine the GM85 mobile digital radiography (DR) system.

Samsung Electronics showcases the GM85 Digital Radiography (DR) system which received 510(k) FDA clearance November 17 for the US market, at the Radiological Society of North America (RSNA) 2016 Annual Meeting at McCormick Place in Chicago. At RSNA booth #4735 (South Building, Hall A), Samsung demonstrates the ultimate driving experience for radiologists and technicians by offering the “GM85 Driving Event”.

“Celebrating our fifth year participating at RSNA, the largest radiology meeting, we would like to thank our valued customers and partners for their ongoing trust and support of our medical imaging innovations,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “Listening to our customers’ needs and acting swiftly to fulfill them has led to Samsung’s fast growth in radiology.”

Visitors to Samsung Electronics’ booth at the Radiological Society of North America’s (RSNA) 2016 annual meeting in Chicago examine the GM85 mobile digital radiography (DR) system.

Along with the GM85, Samsung will showcase a wide range of medical imaging solutions from premium mobile digital X-ray to advanced ultrasound systems. Moreover, new clinical research showing how Samsung’s latest ultrasound technology drives better patient care will be presented at its RSNA Corporate Symposium session Monday 8:30 a.m. – 10:00 a.m. in Room S101AB. Register to attend here.

“Our products continue to prove their versatility as more healthcare providers find new innovative ways to use them,” said Philip Sullivan, Samsung NeuroLogica President and CEO. “RSNA is a great venue for radiologists to learn the diverse ways we are helping hospitals, clinicians and patients.”

Visitors were also given a chance to experience the mobile DR system for themselves.

On display at Samsung’s booth are the following technologies:

Digital Radiography (DR)

GM85 [FDA 510(k) cleared November 17, 2016]

• Easy Navigating with Compact Design: With 555mm narrow width and weighing in at a light 349kg, the GM85 allows easy access around tight spaces, even in elevators. A collapsible column gives users clear visibility when moving the system and broadens access to smaller spaces. Adaptive soft-driving control and front-bumper sensor also help make navigation safer.
• Optimized Workflow with Enhanced Usability: SID (Source to Image Distance) Guide supports detailed device positioning with multiple SID settings. S-Align displays the detector’s angle to the THU (Tube Head Unit) for precise alignment to enhance image quality. Quick-positioning allows handle-free, precise body movement by simple button clicks on the THU and optimizes workflow, enabling users to save time.
• Advanced Imaging Technology for Superior Image Quality: S-Vue, the advanced imaging engine, enhances image sharpness and clarity. SimGrid provides high-quality images without using a conventional grid, reducing scatter radiation effects. Also, radiographers can lower retake rates as S-Vue eliminates alignment errors that often occur with a conventional grid.

GC85A (Advanced Applications) adds new features to radiography workflows:

• Fast Stitching: Our upgraded stitching technology reduces process time by 31% compared to the original GC85A. Increased process speed means radiographers receive exam images more quickly. Fast stitching helps lessen the burden on patients who find it difficult to stand for an extended period of time and leave the x-ray room faster than before.
• SimGrid: This feature streamlines workflow because it operates without a portable grid, reducing operator wrist overload. SimGrid also eliminates alignment errors that often occur with portable grids, reducing retake rates and increasing patient satisfaction.
• Bone Suppression: Clarity of soft tissue is improved when suppressing the appearance of bones in chest images.

The booth showcased 8 examples of the GM85 mobile digital radiography (DR) system for users’ examination.

Portable Computed Tomography (CT)

The BodyTom and CereTom portable systems continue to prove their versatility as they are increasingly adopted and utilized in a wide range of market applications such as mobile stroke units, brachytherapy suites and proton therapy centers, deep brain stimulation and even veterinarian hospitals.

CereTom receives accolades as more mobile stroke treatment units implement the CT scanner:

• The use of CereTom-equipped mobile stroke units expands to several new cities, including New York City, Chicago, and Trenton, New Jersey
• CereTom was awarded a showcase spot among 14 medical innovations before thousands of hospital executives at Premier Inc.’s Annual Innovation Celebration during the company’s 2016 Breakthroughs Conference and Exhibition June 21 for healthcare providers.

BodyTom expands into new care paths as radiologists find more value:

• The University of Texas MD Anderson Cancer Center in Houston, Texas added BodyTom® CT, the world’s first portable, full-body, 32-slice CT (computed tomography) scanner to its Proton Therapy Center and is now treating patients at the facility using images from the scanner.
• The University of Wisconsin (UW) Carbone Cancer Center in Madison recently incorporated BodyTom® technology into its radiation oncology brachytherapy planning process.
• Willis-Knighton Cancer Center in Shreveport, La., also added BodyTom® CT to its brachytherapy suite.

The booth also included an ambulance equipped with Samsung Electronics’ acclaimed CereTom portable computed tomography (CT) scanner – a versatile system utilized in mobile stroke units and a range of other emergency applications.

Ultrasound

RS80A with Prestige – live scanning demos at our RSNA booth – offers cutting-edge features:

• CEUS+: On the heels of the recent FDA approval of contrast-enhanced ultrasound for liver lesions in adults and pediatrics, Samsung introduces its latest contrast-enhanced ultrasound imaging, CEUS+. The RS80A premium ultrasound system applying sophisticated imaging technology that empowers user’s confident diagnosis. The superb resolution and improved uniformity help users acquire better clarity in the near field. Its automatic brightness-control feature optimizes imaging in real-time, providing users with enough time to diagnose. The CEUS+ also improves the diagnosis of small lesions, and its clear expression of tissue boundaries helps users to achieve interventional procedures with ease and accuracy.
• S-Detect^TM for Breast [pending FDA 510(k) clearance, not yet available in the U.S.] – Applying data from 10,000 breast exams to ultrasound imaging, S-Detect helps radiologists understand characteristics of breast lesions to determine whether they’re malignant or benign in a few clicks. The S-Detect^TM provides faster and more accurate results by adopting a big-data, deep-learning algorithm in lesion segmentation, characteristic analysis and assessment processes.

A Samsung representative explains the intricacies of the contrast-enhanced CEUS+ ultrasound imaging system, which provides clear and uniform images for more accurate diagnoses.

For more information on Samsung’s global medical imaging technologies, please visit www.samsungmedicalsolution.com. At RSNA visit booth #4735 (South Building, Hall A) and stay up-to-date by following the Samsung NeuroLogica Twitter feed @SamsungHealthUS.

About NeuroLogica

NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of computed tomography, is also the U.S. headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit http://www.SamsungNeuroLogica.com.

Samsung Electronics will be participating in this year’s Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the world’s largest radiology conference, to unveil its latest innovations and contributions in healthcare.

Come visit us at Chicago’s McCormick Place (South Hall A: #4735) from November 27 to December 2.

For the latest information about Samsung’s healthcare events, please follow the link below:

http://samsungmedicalsolution.com/en/common/eventViewList

For a sneak peek into our latest radiology product please follow the link below:

http://gm85.samsungmedicalsolution.com/

Visitors awaiting Samsung Electronics’ CT unveiling at the RSNA’s 101st annual meeting on November 28.

Samsung Electronics is strengthening its commitment to delivering fast, reliable, smart and innovative diagnostic solutions for healthcare providers by debuting the newest additions to its portfolio, on display at the Radiological Society of North America (RSNA) Annual Meeting at McCormick Place in Chicago. This week at booth #7313 (North Building, Hall B), product specialists will be on hand demonstrating Samsung’s range of solutions in Computed Tomography (CT), Ultrasound and Digital Radiography (DR) systems, which are all designed to enrich the quality of care and workflow, and enhance the patient experience.

“Through our innovative designs and advanced technologies, we remain committed to delivering new solutions, like the NExCT 7 and the RS80A with Prestige, that unlock workflow efficiencies for medical professionals as well as improve patients’ lives,” said Soo-In Cho, President and Head of the Health & Medical Equipment Business at Samsung Electronics Co., Ltd. “By leveraging the combination of Samsung imaging technology and user-inspired design, we will continue to deliver on our promise of fast, easy and accurate diagnostic solutions for our customers in the healthcare community.”

Wayne Spittle, Executive Vice President of Samsung Medison, introducing the NExCT 7, Samsung’s first CT scanner.

Computed Tomography (CT) Segment

Samsung’s CT imaging solutions are used throughout the world in intensive care units, neurosurgical operating rooms, emergency departments, stroke centers and other key clinical areas. Debuting at RSNA is:

• NExCT 7 – the first premium CT scanner from Samsung features high resolution designed to improve diagnostic confidence in advanced and routine exams reducing the radiation dose as low as reasonably achievable and ensuring a fast and efficient workflow. Some features of the NExCT7 are FDA 510(k) pending.

• Portable CT – Samsung will be showcasing the latest in software and hardware enhancements across its portable CT product line. These upgrades improve user satisfaction and streamline workflow, and both systems are now compliant with the Smart Dose (XR-29) radiation dose reporting standard.

The BodyTom and CereTom portable systems continue to prove their versatility as they are increasingly adopted and utilized in a wide range of market applications such as mobile stroke units, brachytherapy suites, proton therapy centers, deep brain stimulation and even veterinarian hospitals.

Ultrasound Segment

Samsung continues to enhance the user experience with its cutting-edge diagnostic ultrasound devices around the world and across various medical fields. On display at RSNA are:

• RS80A with Prestige – now available in the U.S. market, this system features advanced technical capabilities built on the successes of Samsung technologies. Product features include:

• S-Fusion to enable simultaneous localization of lesions with a real-time ultrasound image supported by other modalities’ 3D data sets. Fusion speed and accuracy are the strengths of S-Fusion.
• S-Shearwave to detect the velocity of the shearwave transmitted through the targeted lesion and display the numerical measurement of stiffness.
• E-Breast*: this is the function for breast lesion exam, which calculates the strain between the area of the suspected lesion (ROI) and normal breast fat and displays the results.
• E-Thyroid*: This function assists with the diagnosis of thyroid lesions. The ROI is used to show the contrast of an elastogram.*The strain ratio value is a relative value regarding quantification, not an absolute value.

• HS70A – designed for hospital and private care. This system has a flexible architecture to meet the clinical needs of varied users. The HS70A offers a complete Radiology and Cardiovascular solution, including technologies migrated from the premium radiology RS80A platform. Features include S-Detect, which uses Breast Imaging-Reporting, and Data System (BI-RADS®) scores for analysis and classification of suspicious lesions.

Digital Radiography (DR) Segment

Samsung’s DR systems combine advanced imaging technology, award-winning design and user-friendly automated workflows to meet the demands of 21st century radiology departments. Products on display at RSNA include:

• GC85A – a DR system offering streamlined workflow, diagnostic confidence and improved total cost of ownership. The GC85A features imaging engine S-Vue, ensuring consistency with high quality, convenient setting of contrast and improved sharpness and clarity, S-Share to support unique clinical needs and continuous care with increased connectivity, and Smart Control for one-touch precise positioning.
• GM60A – a mobile Digital Radiography system that delivers high-quality imaging directly to the patient’s bedside. Advanced mobility allows use in the patient room, emergency room, operating room and the intensive care unit, and has advanced features, including S-Detector and S-Vue imaging technologies to deliver accurate diagnoses while ensuring reliable operation with enhanced usability. Additionally, the telescopic column ensures fast navigation by securing a clear view for users.

For more information about Samsung’s showcase at RSNA, please visit http://www.samsung.com/rsna2015.

To learn more about Samsung’s healthcare work, please visit samsung.com/global/business/healthcare/.

About NeuroLogica

NeuroLogica, a healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of computed tomography, is also the U.S. headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit www.SamsungNeuroLogica.com.